Transactions
2
Insider / Lyell Immunopharma, Inc.
Aguirre Jarrad Mattieu
Chief Medical Officer at Lyell Immunopharma, Inc.
- Company
- Lyell Immunopharma, Inc.
- Ticker
- LYEL
- First filing on record
- September 10, 2026
- Latest trade on record
- October 12, 2026
- SEC filings
- EDGAR ↗
Aguirre Jarrad Mattieu, Chief Medical Officer at Lyell Immunopharma, Inc., has disclosed 2 transactions in LYEL since September 10, 2026: 0 purchases (0 open-market buys) and 1 sale, worth about $3,642 at the reported prices. The latest was filed October 13, 2026, 1 day after the trade.
Open-market buys
0
Sales
1
Avg. disclosure lag
0.5d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Aguirre Jarrad Mattieu made no purchases and 1 sale worth $4K, plus 1 other transaction. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Aguirre Jarrad Mattieu has traded 1 stock on record; the largest by dollars is LYEL.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 1 | 47,500 | — |
| S | Open-market sale | 1 | 422 | $3,642 |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 2 | 0 | 1 · $3,642 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| LYEL | Sell S | October 12, 2026 | October 13, 2026 | 1d | 422 | $9 | $3,642 | Form 4 ↗ | ||
| LYEL | Other A | September 10, 2026 | September 10, 2026 | 0d | 47,500 | — | — | derivative | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 13, 2026 | Form 4 | 0002150331-26-000003 | 1 | published | EDGAR ↗ |
| September 10, 2026 | Form 4 | 0002150331-26-000002 | 1 | published | EDGAR ↗ |
Other insiders at Lyell Immunopharma, Inc.
- GLAXOSMITHKLINE PLC Insider 33 rows
- Hill Stephen J. Chief Operating Officer 2 rows
- Lee Gary K. Chief Scientific Officer 2 rows
- Seely Lynn President and CEO 2 rows
- Bulis Veronica Sanchez VP, Corporate Controller 1 row
- Innovative Cellular Therapeutics Holdings Ltd Insider 1 row
- Shook David Chief Medical Officer 1 row
Everyone on file, with contracts and lobbying under the company's name: Lyell Immunopharma, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 2 | September 10, 2026 | October 13, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.